Hikma Advances $250m Buyback With Fresh Purchase and Share Cancellation

The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).

Hikma Pharmaceuticals has continued executing its previously announced $250 million share repurchase programme, buying 244,980 ordinary shares on 4 March 2026 at a volume-weighted average price of 1,254.07 pence. The company intends to cancel these shares, and since 26 February it has acquired 1,027,719 shares for £13.2 million, reducing free float and leaving 220,858,734 voting shares in issue.

The transaction, carried out through Citigroup Global Markets on the London Stock Exchange, increases the number of shares held in treasury to 12,833,233. By shrinking its share base, Hikma is enhancing capital returns to shareholders and potentially boosting earnings per share, underlining management’s confidence in the group’s financial position.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2000.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational generic and specialty drug manufacturer listed in London and on Nasdaq Dubai. The company focuses on supplying injectable, branded, and non-branded generic medicines to hospitals and healthcare systems in developed and emerging markets.

Average Trading Volume: 1,060,088

Technical Sentiment Signal: Sell

Current Market Cap: £2.74B

Learn more about HIK stock on TipRanks’ Stock Analysis page.